Marcain-Adrenalin 2.5 mg/ ml / 5 mikrog/ ml Norja - norja - Statens legemiddelverk

marcain-adrenalin 2.5 mg/ ml / 5 mikrog/ ml

aspen pharma trading limited - bupivakainhydroklorid / adrenalintartrat - injeksjonsvæske, oppløsning - 2.5 mg/ ml / 5 mikrog/ ml

Xylocain Adrenalin 10 mg/ ml / 5 mikrog/ ml Norja - norja - Statens legemiddelverk

xylocain adrenalin 10 mg/ ml / 5 mikrog/ ml

aspen pharma trading limited - lidokainhydroklorid / adrenalintartrat - injeksjonsvæske, oppløsning - 10 mg/ ml / 5 mikrog/ ml

Xylocain Dental Adrenalin 20 mg/ ml / 12.5 mikrog/ ml Norja - norja - Statens legemiddelverk

xylocain dental adrenalin 20 mg/ ml / 12.5 mikrog/ ml

dentsply detrey gmbh - lidokainhydroklorid / adrenalintartrat - injeksjonsvæske, oppløsning - 20 mg/ ml / 12.5 mikrog/ ml

Edistride Euroopan unioni - norja - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - legemidler som brukes i diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillegg til andre legemidler til behandling av type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Forxiga Euroopan unioni - norja - EMA (European Medicines Agency)

forxiga

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - legemidler som brukes i diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillegg til andre legemidler til behandling av type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Natriumklorid B. Braun 9 mg/ ml Norja - norja - Statens legemiddelverk

natriumklorid b. braun 9 mg/ ml

b. braun melsungen ag - natriumklorid - oppløsningsvæske til parenteral bruk - 9 mg/ ml

Natriumklorid Fresenius Kabi 9 mg/ ml Norja - norja - Statens legemiddelverk

natriumklorid fresenius kabi 9 mg/ ml

fresenius kabi norge as - halden - natriumklorid - oppløsningsvæske til parenteral bruk - 9 mg/ ml

Sterile water Fresenius Kabi - Norja - norja - Statens legemiddelverk

sterile water fresenius kabi -

fresenius kabi norge as - halden - vann til injeksjonsvæsker - oppløsningsvæske til parenteral bruk

Sterilt vann B. Braun - Norja - norja - Statens legemiddelverk

sterilt vann b. braun -

b. braun melsungen ag - vann til injeksjonsvæsker - oppløsningsvæske til parenteral bruk

Sterilt vann Baxter Viaflo - Norja - norja - Statens legemiddelverk

sterilt vann baxter viaflo -

baxter medical ab - vann til injeksjonsvæsker - oppløsningsvæske til parenteral bruk